Effect of vitamin D & magnesium on inflammation and obesity- induced depressive symptoms
Phase 3
Recruiting
- Conditions
- Obesity.Obesity due to excess calories
- Registration Number
- IRCT20090822002365N23
- Lead Sponsor
- ational Institute for Medical Research Development
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 80
Inclusion Criteria
Obese women with BMI range of 30-40 kg/m2
Aged 18-50 years
Serum 25(OH)D < 30 ng/ml
No autoimmune disease, renal, hepatic, parathyroid, and gastrointestinal disorders
No taking vitamin D and/or magnesium supplements or anti-depressant and anti-inflammatory drugs
Exclusion Criteria
Affecting by any acute disease during the study
Unwillingness to continue the study
Less than 90% compliance with the treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum level of TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum TNF-a levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany).
- Secondary Outcome Measures
Name Time Method Serum level of IL-6. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum IL-6 levels will be assessed by ELISA and Bender Med kit (Bender Med, Germany).;Serum level of BDNF. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum BDNF levels will be assessed by ELISA and ZellBio kit (ZellBio, Germany).;Serum level of SIRT-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: Serum SIRT-1 levels will be assessed by ELISA and ZellBio kit (ZellBio, Germany).;Mood. Timepoint: Before and 8 weeks after intervention. Method of measurement: Beck Depression Inventory.